Naltrexone

Titlesort descending Average Rating
Early outcomes following low dose naltrexone enhancement of opioid detoxification. 60.00%
Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. 95.00%
63 year old woman with stage III malignant melanoma 100.00%
71 year old woman, Pancraetic cancer with liver and lung metastasis. 90.00%
75 year old man, Prostate Cancer with bone and liver metastasis 100.00%
Anxiety- and depressive-like responses and c-fos activity in preproenkephalin knockout mice: oversensitivity hypothesis of enkephalin deficit-induced posttraumatic stress disorder. 60.00%
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multipl 80.00%
Immunomodulatory effects of opioids. 90.00%
Low Dose naltrexone 100.00%
Low dose naltrexone for induction of remission in Crohn's disease. 90.00%
Low-dose naltrexone for disease prevention and quality of life. 95.00%
Low-dose naltrexone for the treatment of irritable bowel syndrome: a pilot study. 90.00%
Low-dose naltrexone therapy improves active Crohn's disease. 90.00%
Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease 80.00%
Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. 80.00%
Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. 100.00%
Reduced cannabis use after low-dose naltrexone addition to opioid detoxification. 70.00%
Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone 100.00%
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic ca 90.00%
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. 90.00%
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alp 90.00%
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain 80.00%
Tolerance to the anticonvulsant effect of morphine in mice: blockage by ultra-low dose naltrexone. 60.00%